ERBB2 and breast carcinoma: Compound II (Fig. 1) exhibited the highest antiproliferative efficacy against EGFR (IC50 = 0.122 μM) and HER-2 (IC50 = 0.078 μM) kinases, as well as MCF-7 breast cancer.